<DOC>
	<DOC>NCT01645826</DOC>
	<brief_summary>The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.</brief_summary>
	<brief_title>Efficacy Study of Cardizem in Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Adult participants Confirmed WHO class I pulmonary arterial hypertension Nitric Oxide NonResponders on right heart catheterization Experience dyspnea, NYHA IIIIV with poor oxygenation and quality of life despite standard treatments Must be able to swallow medications Pulmonary hypertension secondary to 1) elevations in pulmonary venous pressures (i.e. left heart disease), 2) chronic hypoxemic states from lung diseases such as COPD, sleepdisordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude and developmental abnormalities 3) chronic thromboembolic disease, 4) sarcoidosis, 5) Lymphangiomyomatosis, 5) Pulmonary Langerhans Cell Histiocytosis Already on a calcium channel blocker Systolic blood pressure less than 90 Heart rate less than 55 Pregnant Cannot sign informed consent Right heart failure Pulmonary Venoocclusive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>